Analysts expect Revance Therapeutics Inc (NASDAQ:RVNC) to announce earnings of ($0.98) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Revance Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.89) and the lowest estimate coming in at ($1.05). Revance Therapeutics reported earnings per share of ($0.95) in the same quarter last year, which suggests a negative year over year growth rate of 3.2%. The company is expected to report its next earnings results on Monday, February 26th.
On average, analysts expect that Revance Therapeutics will report full-year earnings of ($3.74) per share for the current year, with EPS estimates ranging from ($3.96) to ($3.25). For the next year, analysts forecast that the firm will post earnings of ($3.46) per share, with EPS estimates ranging from ($4.24) to ($2.84). Zacks’ EPS averages are a mean average based on a survey of analysts that follow Revance Therapeutics.
Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.06). The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.64) earnings per share.
Shares of Revance Therapeutics (NASDAQ:RVNC) traded up $0.20 during mid-day trading on Tuesday, hitting $33.95. The company had a trading volume of 284,012 shares, compared to its average volume of 337,378. The company has a market capitalization of $1,214.53, a PE ratio of -8.93 and a beta of 1.62. Revance Therapeutics has a fifty-two week low of $18.00 and a fifty-two week high of $37.45.
In other Revance Therapeutics news, CFO Lauren P. Silvernail sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $26.83, for a total transaction of $268,300.00. Following the completion of the transaction, the chief financial officer now directly owns 59,006 shares in the company, valued at $1,583,130.98. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO L Daniel Browne sold 7,600 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $24.94, for a total transaction of $189,544.00. Following the transaction, the chief executive officer now owns 133,188 shares of the company’s stock, valued at $3,321,708.72. The disclosure for this sale can be found here. 18.86% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in the company. Pura Vida Investments LLC acquired a new position in shares of Revance Therapeutics during the third quarter worth $1,378,000. Schwab Charles Investment Management Inc. increased its holdings in shares of Revance Therapeutics by 4.9% during the third quarter. Schwab Charles Investment Management Inc. now owns 117,258 shares of the biopharmaceutical company’s stock worth $3,231,000 after buying an additional 5,501 shares in the last quarter. EAM Investors LLC increased its holdings in shares of Revance Therapeutics by 113.9% during the third quarter. EAM Investors LLC now owns 72,518 shares of the biopharmaceutical company’s stock worth $1,998,000 after buying an additional 38,621 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Revance Therapeutics during the third quarter worth $144,000. Finally, Alps Advisors Inc. increased its holdings in shares of Revance Therapeutics by 11.1% during the third quarter. Alps Advisors Inc. now owns 30,351 shares of the biopharmaceutical company’s stock worth $836,000 after buying an additional 3,027 shares in the last quarter. Institutional investors own 76.69% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/01/21/1715137.html.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.